A method for preparing a human plasma-derived hepatitis B immunoglobulin preparation, comprising the steps of: (a) dissolving a Cohn fraction II containing human plasma-derived hepatitis B immunoglobulin, collected from a healthy donor who suffered from hepatitis B or who was additionally immunized with a hepatitis B vaccine, and then obtaining a fraction II solution by filtration; (b) dialyzing and/or concentrating the obtained fraction II solution using ultrafiltration/diafiltration until the osmotic pressure of the dialyzed and concentrated solution reaches 10 mOsmol/kg or lower, followed by adjusting the pH to 5.95-6.35, subjecting the dialyzed and/or concentrated solution to anion exchange chromatography, and then recovering a fraction not attached to a column used to perform the anion exchange chromatography, wherein the anion exchange chromatography uses a diethylaminoethyl (DEAE)-based anion exchange resin; (c) treating the recovered fraction with a solvent and/or a detergent to inactivate viruses, and subjecting the treated fraction to cation exchange chromatography under pH of 5.6 to 6.0 to remove the solvent and/or the detergent, and thrombotic substances, wherein the solvent is tri(n-butyl) phosphate (TNBP), and the detergent is at least one selected from among polysorbate 80, Triton X-100, and Triton X-45, wherein the cation-exchange chromatography uses a Sephadex-based cation exchange resin; (d) dialyzing and/or concentrating an eluate obtained from the cation exchange chromatography; (e) filtering the dialyzed and/or concentrated solution, thereby obtaining a human hepatitis B immunoglobulin; (f) adding a stabilizer to the human hepatitis B immunoglobulin and adjusting pH of the immunoglobulin solution to 3.5-4.5 after addition of the stabilizer; and (g) preparing a human hepatitis B immunoglobulin for intravenous injection after the pH adjusted immunoglobulin solution being subjected to bacterial filtration and adjusting pH of the immunoglobulin solution to 4.0-4.5 after the bacterial filtration. (a) dissolving a Cohn fraction II containing human plasma-derived hepatitis B immunoglobulin, collected from a healthy donor who suffered from hepatitis B or who was additionally immunized with a hepatitis B vaccine, and then obtaining a fraction II solution by filtration; (b) dialyzing and/or concentrating the obtained fraction II solution using ultrafiltration/diafiltration until the osmotic pressure of the dialyzed and concentrated solution reaches 10 mOsmol/kg or lower, followed by adjusting the pH to 5.95-6.35, subjecting the dialyzed and/or concentrated solution to anion exchange chromatography, and then recovering a fraction not attached to a column used to perform the anion exchange chromatography, wherein the anion exchange chromatography uses a diethylaminoethyl (DEAE)-based anion exchange resin; (c) treating the recovered fraction with a solvent and/or a detergent to inactivate viruses, and subjecting the treated fraction to cation exchange chromatography under pH of 5.6 to 6.0 to remove the solvent and/or the detergent, and thrombotic substances, wherein the solvent is tri(n-butyl) phosphate (TNBP), and the detergent is at least one selected from among polysorbate 80, Triton X-100, and Triton X-45, wherein the cation-exchange chromatography uses a Sephadex-based cation exchange resin; (d) dialyzing and/or concentrating an eluate obtained from the cation exchange chromatography; (e) filtering the dialyzed and/or concentrated solution, thereby obtaining a human hepatitis B immunoglobulin; (f) adding a stabilizer to the human hepatitis B immunoglobulin and adjusting pH of the immunoglobulin solution to 3.5-4.5 after addition of the stabilizer; and (g) preparing a human hepatitis B immunoglobulin for intravenous injection after the pH adjusted immunoglobulin solution being subjected to bacterial filtration and adjusting pH of the immunoglobulin solution to 4.0-4.5 after the bacterial filtration.